Fiasp Insulin
Fiasp Insulin
$0.00
Fiasp (fast-acting insulin aspart) is a rapid-onset mealtime insulin used in adults, adolescents, and children (from 1 year of age) with diabetes. It’s designed to be injected at the start of a meal—or within 20 minutes after—to quickly lower post-m
Delivery
5-7 day
In Stock
Yes
Guaranteed
Source Canadian PharmacyFiasp is a modified insulin aspart formulation (100 U/mL) that includes nicotinamide (vitamin B₃) and L‑arginine, enabling insulin to enter the bloodstream about 5 minutes faster than standard rapid-acting insulins like NovoRapid/Novolog.
Indications & Dosing
-
Approved for adults, adolescents, and children aged 1+ with type 1 or type 2 diabetes.
-
Administered via subcutaneous injection, insulin pen, vial, or pump.
-
Dosed up to 2 minutes before a meal, or within 20 minutes after starting it for convenience.
Typically used alongside a basal or long-acting insulin as part of a basal-bolus regimen.
Indications & Dosing
-
Approved for adults, adolescents, and children aged 1+ with type 1 or type 2 diabetes.
-
Administered via subcutaneous injection, insulin pen, vial, or pump.
-
Dosed up to 2 minutes before a meal, or within 20 minutes after starting it for convenience.
-
Typically used alongside a basal or long-acting insulin as part of a basal-bolus regimen.
Pharmacokinetics & Pharmacodynamics
-
Onset occurs within 2.5 minutes; peak effect at ~1–3 hours; duration of action lasts 3–5 hours.
-
Studies show Fiasp rapidly lowers post-prandial glucose more effectively than NovoRapid
Benefits
-
Faster action offers tighter control of post-meal blood sugar and added flexibility—useful for those who forget pre-meal dosing.
-
Comparable HbA1c reductions and long-term glycemic control when compared to standard rapid-acting insulin.
In Summary
Fiasp is a modern, fast-acting mealtime insulin offering rapid onset and flexible dosing—ideal for tighter post-meal blood sugar control. It fits seamlessly into multiple delivery systems (pens, pump, vials), but its speed also carries an elevated risk of early hypoglycaemia, and some patients experience injection-site reactions or diminishing effects over time. Careful monitoring and individualized dosing are key to optimizing its use.
Let me know if you’d like a comparison with other fast-acting insulins like Lyumjev, pump compatibility specifics, or patient management tips!